AUS
NZ
UK
CA
USA
IND
Highlights:
- Adjusted Profit Before Tax Expected to Exceed £35 Million
- Strong Performance Across ABS and PIC Divisions
- Progress in PRRS1 Resistant Pig Programme Regulatory Approval
Genus (LSE:GNS), a global leader in animal genetics, expects to report a better-than-expected profit for the first half of FY25, with significant contributions from both its ABS and PIC divisions.
Genus has delivered a strong financial performance in the first half of FY25, with the Board now expecting a Group adjusted profit before tax of at least £35 million, surpassing previous expectations. This result has been primarily driven by ongoing initiatives under the company’s Value Acceleration Programme, particularly within its ABS division, which continues to meet expectations.
The PIC division also exceeded expectations, fueled by higher volumes and adjusted operating profit growth in both the Americas and Asia regions.
A key development in Genus’s innovative PRRS1 Resistant Pig programme is its continued progress through the regulatory process with both the U.S. Food and Drug Administration (FDA) and other international regulators, bringing the company closer to a potential breakthrough in the animal genetics field.
Despite a currency headwind expected to be in the range of £8 million to £9 million, the Board anticipates FY25 adjusted profit before tax to be at the top end of market expectations, further solidifying the company's positive outlook for the remainder of the fiscal year.
Genus will announce its interim results for the six months ending 31 December 2024 on 27 February 2025.
